Wu 2017b.

Methods	Study design: Randomised clinical trial Study duration: February 2013 to May 2015 Duration of follow‐up: Not reported Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by pathology and images; with normal renal and haematopoietic function; tumour number ≤ 5; no extrahepatic metastasis Exclusion criteria: With other serious diseases; with mental disease Age (mean ± SD, range): TACE + MWA: 42.1 ± 1.5 years, 25‐60 years; TACE alone: 43.1 ± 1.3 years, 26‐60 years Male (n/total): TACE + MWA: 20/35; TACE alone: 21/35
Interventions	TACE + MWA group (n = 35): TACE: Chemotherapeutic drugs: cisplatin and epirubicin. Three sessions of TACE treatment were performed for each patient, with an interval of 4 weeks. MWA: CT‐guided MWA. Output power of 50 W TACE group (n = 35): Chemotherapeutic drugs: cisplatin and epirubicin. Three sessions of TACE treatment were performed for each patient, with an interval of 4 weeks.
Outcomes	Recurrence rate, classified as complete response, partial response, stable disease, and progression Tumour response rate
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.